Our results

Real numbers, no empty promises

Everything you see here comes directly from our platform. Transparent about what our clients achieve together.

Updated today

Lost collectively

0kg

Combined weight loss across all our clients, measured through weekly check-ins.

Average per client

0kg

Based on clients who have been following the programme for at least 6 months.

0

Check-ins completed

0

Modules completed

0

Messages with care team

0

Community messages

< 2 hoursaverage response time from our care team

More than just weight

Losing weight is about more than a number on the scale. How do our clients experience the programme and their health?

Waist circumference

-0cm

average reduction in waist circumference

Blood pressure

-0mmHg

average systolic reduction

Satisfaction

0%

rate their journey as "good" or "great"

Our mission

The Netherlands 1,000,000 kg lighter

Together with our clients, we're working towards a million kilos of weight loss. We want to make a real difference in the health of people living with excess weight.

4.109 kg

Total weight lost by our clients.

1,000,000 kg

Our goal on the horizon.

Experiences

What our clients say

Trustpilot4.8/5
5
4
3
2
1
Google5.0/5
5
4
3
2
1
Member feedback94% positive
🤩
😁
😊
😕
â˜šī¸

More than just losing weight

Save money by losing weight

5% less on groceries, 20% lower risk of a heart attack and 14 fewer sick days a year. See what peer-reviewed research shows.

Read more

Blog about medical weight loss

Read our articles about medical weight loss, lifestyle, nutrition, medication, obesity, exercise and healthy living.

Ontsteking en obesitas: waar start de vicieuze cirkel?

Ontsteking en obesitas: waar start de vicieuze cirkel?

Een diepgaande blik op de complexe relatie tussen obesitas en chronische ontsteking, hoe ze elkaar versterken, en hoe leefstijl en nieuwe behandelingen zoals GLP-1 medicatie deze cirkel kunnen doorbreken.

Eerste GLP-1 medicijn goedgekeurd voor MASH in Europa

Eerste GLP-1 medicijn goedgekeurd voor MASH in Europa

Europa keurt eerste GLP-1 medicijn goed voor MASH-behandeling. Semaglutide (Kayshild) biedt hoop voor miljoenen met leverziekte.

GLP-1 receptoragonisten en hun rol in het verlagen van infectierisico's

GLP-1 receptoragonisten en hun rol in het verlagen van infectierisico's

Ontdek hoe GLP-1 receptoragonisten niet alleen diabetes behandelen, maar ook het risico op ernstige infecties verlagen. Lees meer over deze veelbelovende bevindingen!